457 related articles for article (PubMed ID: 33262196)
1. High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39
Liu T; Tan J; Wu M; Fan W; Wei J; Zhu B; Guo J; Wang S; Zhou P; Zhang H; Shi L; Li J
Gut; 2021 Oct; 70(10):1965-1977. PubMed ID: 33262196
[TBL] [Abstract][Full Text] [Related]
2. The CD39
Zou F; Tan J; Liu T; Liu B; Tang Y; Zhang H; Li J
Mol Ther; 2021 May; 29(5):1794-1807. PubMed ID: 33484968
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma.
Dong LQ; Peng LH; Ma LJ; Liu DB; Zhang S; Luo SZ; Rao JH; Zhu HW; Yang SX; Xi SJ; Chen M; Xie FF; Li FQ; Li WH; Ye C; Lin LY; Wang YJ; Wang XY; Gao DM; Zhou H; Yang HM; Wang J; Zhu SD; Wang XD; Cao Y; Zhou J; Fan J; Wu K; Gao Q
J Hepatol; 2020 May; 72(5):896-908. PubMed ID: 31887370
[TBL] [Abstract][Full Text] [Related]
4. Bystander CD8
Simoni Y; Becht E; Fehlings M; Loh CY; Koo SL; Teng KWW; Yeong JPS; Nahar R; Zhang T; Kared H; Duan K; Ang N; Poidinger M; Lee YY; Larbi A; Khng AJ; Tan E; Fu C; Mathew R; Teo M; Lim WT; Toh CK; Ong BH; Koh T; Hillmer AM; Takano A; Lim TKH; Tan EH; Zhai W; Tan DSW; Tan IB; Newell EW
Nature; 2018 May; 557(7706):575-579. PubMed ID: 29769722
[TBL] [Abstract][Full Text] [Related]
5. 4-1BB Delineates Distinct Activation Status of Exhausted Tumor-Infiltrating CD8
Kim HD; Park S; Jeong S; Lee YJ; Lee H; Kim CG; Kim KH; Hong SM; Lee JY; Kim S; Kim HK; Min BS; Chang JH; Ju YS; Shin EC; Song GW; Hwang S; Park SH
Hepatology; 2020 Mar; 71(3):955-971. PubMed ID: 31353502
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of tumor-reactive CD4
Palomero J; Panisello C; Lozano-Rabella M; Tirtakasuma R; Díaz-Gómez J; Grases D; Pasamar H; Arregui L; Dorca Duch E; Guerra Fernández E; Vivancos A; de Andrea CE; Melero I; Ponce J; Vidal A; Piulats JM; Matias-Guiu X; Gros A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36581331
[TBL] [Abstract][Full Text] [Related]
7. Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
Liu F; Zeng G; Zhou S; He X; Sun N; Zhu X; Hu A
Bull Cancer; 2018 May; 105(5):493-501. PubMed ID: 29576222
[TBL] [Abstract][Full Text] [Related]
8. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
9. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
[TBL] [Abstract][Full Text] [Related]
10. Liver-infiltrating CD8(+) lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma.
Ramzan M; Sturm N; Decaens T; Bioulac-Sage P; Bancel B; Merle P; Tran Van Nhieu J; Slama R; Letoublon C; Zarski JP; Jouvin-Marche E; Marche PN; Leroy V
Liver Int; 2016 Mar; 36(3):434-44. PubMed ID: 26215124
[TBL] [Abstract][Full Text] [Related]
11. PD1
Ma J; Zheng B; Goswami S; Meng L; Zhang D; Cao C; Li T; Zhu F; Ma L; Zhang Z; Zhang S; Duan M; Chen Q; Gao Q; Zhang X
J Immunother Cancer; 2019 Nov; 7(1):331. PubMed ID: 31783783
[TBL] [Abstract][Full Text] [Related]
12. Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
Kang HJ; Oh JH; Chun SM; Kim D; Ryu YM; Hwang HS; Kim SY; An J; Cho EJ; Lee H; Shim JH; Sung CO; Yu E
J Hepatol; 2019 Jul; 71(1):91-103. PubMed ID: 30930222
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis.
Yao W; He JC; Yang Y; Wang JM; Qian YW; Yang T; Ji L
Sci Rep; 2017 Aug; 7(1):7525. PubMed ID: 28790445
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating CD39
Qi Y; Xia Y; Lin Z; Qu Y; Qi Y; Chen Y; Zhou Q; Zeng H; Wang J; Chang Y; Bai Q; Wang Y; Zhu Y; Xu L; Chen L; Kong Y; Zhang W; Dai B; Liu L; Guo J; Xu J
Cancer Immunol Immunother; 2020 Aug; 69(8):1565-1576. PubMed ID: 32306075
[TBL] [Abstract][Full Text] [Related]
15. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors.
Duhen T; Duhen R; Montler R; Moses J; Moudgil T; de Miranda NF; Goodall CP; Blair TC; Fox BA; McDermott JE; Chang SC; Grunkemeier G; Leidner R; Bell RB; Weinberg AD
Nat Commun; 2018 Jul; 9(1):2724. PubMed ID: 30006565
[TBL] [Abstract][Full Text] [Related]
16. Global microarray profiling identified
Weng Q; Chen M; Li M; Zheng YF; Shao G; Fan W; Xu XM; Ji J
J Med Genet; 2019 Jan; 56(1):32-38. PubMed ID: 30120213
[TBL] [Abstract][Full Text] [Related]
17. High number of PD-1 positive intratumoural lymphocytes predicts survival benefit of cytokine-induced killer cells for hepatocellular carcinoma patients.
Chang B; Shen L; Wang K; Jin J; Huang T; Chen Q; Li W; Wu P
Liver Int; 2018 Aug; 38(8):1449-1458. PubMed ID: 29356308
[TBL] [Abstract][Full Text] [Related]
18. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells.
Unitt E; Rushbrook SM; Marshall A; Davies S; Gibbs P; Morris LS; Coleman N; Alexander GJ
Hepatology; 2005 Apr; 41(4):722-30. PubMed ID: 15791620
[TBL] [Abstract][Full Text] [Related]
19. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma.
Xie C; Wu H; Pan T; Zheng X; Yang X; Zhang G; Lian Y; Lin J; Peng L
Aging (Albany NY); 2021 Mar; 13(6):8563-8587. PubMed ID: 33714200
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of interleukin-36α correlates with poor prognosis in hepatocellular carcinoma.
Pan QZ; Pan K; Zhao JJ; Chen JG; Li JJ; Lv L; Wang DD; Zheng HX; Jiang SS; Zhang XF; Xia JC
Cancer Immunol Immunother; 2013 Nov; 62(11):1675-85. PubMed ID: 24061617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
